Literature DB >> 2345068

Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs.

Z Zylicz1, D J Wagener, M Garzotto, T B Vree, E van der Kleijn, L A van den Broek, H C Ottenheijm.   

Abstract

N-pentyl-sparsomycin (PSm) is a lipophilic analogue of sparsomycin (Sm), which is a well known inhibitor of protein synthesis. This compound was selected for preclinical pharmacokinetic studies because of its high in vitro and in vivo antitumor activity. In this study in which the drug was evaluated in beagle dogs under anaesthesia, the drug concentrations in plasma, urine and bile samples were determined using high performance liquid chromatography (HPLC). Plasma protein binding was approximately 54%. The mean t1/2 beta was 0.2 hours (12 minutes) and t1/2 tau was 0.75 +/- 0.1 hours (45 +/- 6 minutes). During continuous infusions up to 5.25 hours, the steady state was reached in 3 out of 6 experiments, suggesting that in some cases the real t1/2 tau was longer than measured. PSm was actively reabsorbed from the renal tubuli. This process was saturable at the higher doses. Tubular reabsorption played only a minor role in pharmacokinetics as most of the drug (67%) was eliminated by the non-renal clearance. The non-renal clearance was saturable at higher doses of PSm and was the reason for non-linearity of pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345068     DOI: 10.1007/bf00216921

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  10 in total

1.  OCULAR TOXICITY WITH SPARSOMYCIN (NSC-59729) IN A PHASE I STUDY: A PRELIMINARY REPORT.

Authors:  H P CLOSE; J R MCFARLANE
Journal:  Cancer Chemother Rep       Date:  1964-12

2.  Action of sparsomycin on ribosome-catalysed peptidyl transfer.

Authors:  R E Monro; M L Celma; D Vazquez
Journal:  Nature       Date:  1969-04-26       Impact factor: 49.962

3.  Kinetic modeling of the renal excretion of iodopyracet in the dog.

Authors:  P Hekman; C A van Ginneken
Journal:  J Pharmacokinet Biopharm       Date:  1982-02

4.  Determination of sparsomycin in plasma and urine of the dog by means of reversed-phase high-performance liquid chromatography and first pharmacokinetic results.

Authors:  B Winograd; M J Oosterbaan; E van der Kleijn; R M Liskamp; H C Ottenheijm; D J Wagener
Journal:  J Chromatogr       Date:  1983-06-10

5.  Structure-activity relationships of sparsomycin and its analogues. Octylsparsomycin: the first analogue more active than sparsomycin.

Authors:  R M Liskamp; J H Colstee; H C Ottenheijm; P Lelieveld; W Akkerman
Journal:  J Med Chem       Date:  1984-03       Impact factor: 7.446

6.  Structure-activity relationships of sparsomycin and its analogues. Inhibition of peptide bond formation in cell-free systems and of L1210 and bacterial cell growth.

Authors:  L A van den Broek; R M Liskamp; J H Colstee; P Lelieveld; M Remacha; D Vázquez; J P Ballesta; H C Ottenheijm
Journal:  J Med Chem       Date:  1987-02       Impact factor: 7.446

7.  Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; P Fernandez del Moral; H van Rennes; J M Wessels; B Winograd; E van der Kleijn; T B Vree; U van Haelst; L A van den Broek
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study.

Authors:  L A van den Broek; E Lázaro; Z Zylicz; P J Fennis; F A Missler; P Lelieveld; M Garzotto; D J Wagener; J P Ballesta; H C Ottenheijm
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

9.  Preclinical pharmacokinetics of the antitumor antibiotic deshydroxy-sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; M Garzotto; T B Vree; E van der Kleijn; L A van den Broek; H C Ottenheijm
Journal:  Anticancer Res       Date:  1988 Nov-Dec       Impact factor: 2.480

10.  In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.

Authors:  Z Zylicz; D J Wagener; H van Rennes; E van der Kleijn; P Lelieveld; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.